Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided angiotensin II to reduce kidney damage after cardiac surgery
2021-003088-87Phase 3Active
- Sponsor
- Universität Münster
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute kidney failure (AKF) comparing Angiotensin II with Standard of care (2 arms). Primary endpoint: Primary endpoint: kidney damage biomarker change. Started Sep 2021; status: active.
02
Drugs
Angiotensin II
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2021-003088-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003088-87.